Kidney Cell Metabolism and Scarring in Several Kidney Diseases
Studies kidney tubule metabolism in adults with ANCA vasculitis and other kidney diseases.
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- Paris, FranceSee the site
- Trial code
- Registry title
- Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
- Status
- Recruiting
- People taking part
- 146 people, planned
- Started
- 3 Nov 2025
- Expected to end
- 2 Nov 2029
- Type of study
- Observational, 7 groups
- Record updated
- 30 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who need a first kidney biopsy to find out the cause of their kidney disease. One group has ANCA vasculitis. Other groups have different kidney diseases.
- Age
- 18 to 90 years
- Sex
- All sexes
- Disease stage
- Kidney disease confirmed on the kidney biopsy: ANCA vasculitis, or one of these kidney diseases: interstitial nephritis, minimal change disease, segmental hyalinosis (collapsing form), membranous glomerulopathy, IgA nephropathy or diabetic nephropathy.
- Biomarker or test result
- For the ANCA vasculitis group: ANCA anti-proteinase 3 (PR3) or ANCA anti-myeloperoxidase (MPO) found on the biopsy diagnosis.
Main reasons for not taking part
- Kidney transplant
- On dialysis (hemodialysis or peritoneal dialysis)
- Under legal protection, guardianship or curatorship
- Pregnancy or breastfeeding
- Taking part in another interventional study (except studies on ANCA vasculitis and IgA nephropathy)
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Patients with an indication for initial diagnostic PBR on native kidney
- 18 ans ≥ Age ≤ 90 ans
- Affiliation to french health insurance
- Patient having given consent; For the ANCA vasculitis group:
- Diagnosis of ANCA vasculitis retained on renal biopsy with ANCA anti-proteinase 3 (PR3) or ANCA anti-myeloperoxidase (MPO); For the control groups:
- Diagnosis retained after the renal biopsy
- Interstitial Nephritis
- Or glomerular nephropathy such as minimal change nephropathy
- Or Segmental hyalinosis in itscollapsing form
- Or Extramembranous Glomerulopathy,
- Or glomerulopathy with mesangial IgA deposits
- Or diabetic nephropathy
Who cannot take part
- Kidney transplant patient
- Patient on dialysis (hemodialysis or peritoneal dialysis)
- Patient under legal protection, guardianship or curatorship
- Pregnancy or breastfeeding
- Enrollement in an interventional study except studies relating to ANCA vasculitis and nephropathy with mesangial IgA deposits
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Where in France
- Georges-Pompidou European Hospital, AP-HPParis, FranceContact: Marine LivrozetTaking people
About the trial
What the trial wants to find out
The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.
The 7 groups in the trial
- ANCA Associated Vasculitis
Case
- Extramembranous Glomerulopathy
Control
- Nephrotic Syndrome, Minimal Change
Control
- Interstitial Nephritis
Control
- IgA Nephropathy
Control
- Segmental Hyalinosis
Control
- Diabetic Nephropathy
Control
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
- Plain-language title
- Kidney Cell Metabolism and Scarring in Several Kidney DiseasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07010250, who can take part
- Record updated
- 30 June 2026